Physician profile
Wei Wei Ma
NPI 1063412310
$38,595.70
in general payments reported to CMS, 2019-2025
44 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,055 · 2020: $22K · 2021: $5,551 · 2022: $747 · 2023: $1,676 · 2024: $1,227 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,524 · Education: $47.73 · Travel and Lodging: $43.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,523.72 |
| Education | $47.73 |
| Travel and Lodging | $43.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $15,584.67 | 2019-2025 | Briviact, Fintepla, Zilbrysq |
| Sk Life Science, INC. | $9,945.06 | 2020-2025 | Xcopri |
| Sunovion Pharmaceuticals INC. | $8,954.30 | 2019-2020 | |
| Livanova USA, INC. | $463.71 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Argenx US, INC. | $441.52 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $401.58 | 2022-2025 | |
| Celgene Corporation | $401.57 | 2022-2025 | Zeposia |
| Neurelis, INC. | $286.35 | 2023-2025 | Valtoco |
| Biogen, INC. | $222.25 | 2021-2025 | Vumerity, Tysabri |
| Eisai INC. | $219.06 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $203.91 | 2023-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $164.56 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $158.96 | 2025 | Wainua |
| Averitas Pharma INC. | $107.24 | 2025 | Qutenza |
| Medtronic USA, INC. | $92.02 | 2019 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otter Pharmaceuticals, LLC | $62.40 | 2025 | Sympazan |
| Aucta Pharmaceuticals, INC. | $61.39 | 2024-2025 | Motpoly Xr |
| Grifols USA, LLC | $59.28 | 2025 | Gamunex-C |
| Teva Pharmaceuticals USA, INC. | $55.38 | 2022-2024 | Austedo Xr |
| Janssen Biotech, INC. | $50.49 | 2025 | |
| Impel Pharmaceuticals INC. | $45.04 | 2022-2023 | Trudhesa |
| Aquestive Therapeutics, INC. | $45.01 | 2022 | |
| Medtronic, INC. | $41.05 | 2022 | |
| Sumitomo Pharma America, INC. | $40.16 | 2023 | Aptiom |
| Supernus Pharmaceuticals, INC. | $37.69 | 2025 | Qelbree |
| Lilly USA, LLC | $37.50 | 2022-2024 | Reyvow, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $37.38 | 2023-2025 | Gammagard, Hyqvia |
| Alnylam Pharmaceuticals INC. | $37.04 | 2023-2025 | Onpattro |
| Neurocrine Biosciences, INC. | $34.84 | 2020-2025 | |
| Springworks Therapeutics, INC. | $34.25 | 2024-2025 | Gomekli |
| Octapharma USA, INC. | $33.29 | 2025 | Panzyga |
| Lundbeck LLC | $32.47 | 2024 | Vyepti |
| Relievant Medsystems, INC. | $27.66 | 2023 | Intracept |
| Acadia Pharmaceuticals INC | $24.00 | 2025 | Daybue |
| Merz Pharmaceuticals, LLC | $18.36 | 2025 | Xeomin |
| Immedica Pharma US, INC. | $16.67 | 2024 | |
| Csl Behring | $15.69 | 2025 | Hizentra |
| Kedrion Biopharma, INC. | $15.47 | 2025 | Koate, Kedrab, Gammaked |
| Tonix Medicines, INC. | $15.06 | 2025 | Zembrace Symtouch |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $14.54 | 2025 | |
| Jazz Pharmaceuticals INC. | $14.03 | 2025 | |
| Lemaitre Vascular, INC. | $13.93 | 2025 | Xenosure Biologic Patch |
| Genentech USA, INC. | $13.87 | 2024 | Enspryng, Ocrevus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Wei Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.